When Amgen Inc.'s Blincyto (blinatumomab) gained accelerated approval from the FDA in December to treat patients with relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, or B-cell ALL, the compound turned a new chapter in drug development, heralding the arrival of bispecific antibodies.